Q-omics provides the consensus-scored TANGO6 profile across patient tissues and cancer cell-line models. TANGO6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TANGO6 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TANGO6 protein abundance shows 33,128 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, HNSC, and PDAC as cancer lineages where TANGO6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TANGO6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TANGO6 survival associations across molecular data types. TANGO6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TANGO6 RNA expression–survival associations across cancer types. High TANGO6 expression shows unfavorable associations in MESO, UVM, HNSC and LUSC, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TANGO6 RNA expression.
This table summarizes TANGO6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TANGO6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TANGO6 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in HNSC, COAD and KIRC. The HNSC box plot shows higher TANGO6 RNA expression in tumor versus normal tissue (log2 FC = +0.695, t-test p < 0.001).
This table shows molecular features associated with TANGO6 in patient tissues and cancer cell lines. In patient samples, TANGO6 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TANGO6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
